Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Demonstrate significant bleed reduction in hemophilia A and B
This acquisition marks Max Healthcare's entry into Lucknow
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Subscribe To Our Newsletter & Stay Updated
